Healthcare >> Analyst Interviews >> May 3, 2004


ELEMER PIROS is a senior biotechnology analyst at Rodman & Renshaw, Inc. Previously, Dr. Piros was a buyside biotechnology analyst at Spear, Leeds & Kellogg, now a wholly owned subsidiary of Goldman Sachs. From 1990 to 2000, Dr. Piros conducted academic research in the field of neuroscience, focusing on understanding the molecular mechanism of communication in the nervous system. He has published his findings in peer-reviewed scientific journals. Dr. Piros earned degrees in mathematics and in biology and a PhD in neuroscience at the University of California at Los Angeles. He then completed post-doctoral training at Cornell University Medical College in New York. Currently, Dr. Piros' research universe includes emerging biotechnology companies that develop products addressing the nervous system and cancer. Profile
TWST: What has gone on at Rodman & Renshaw over the past couple of years

in terms of research and coverage you're providing?

Dr. Piros: We started this effort two years ago from scratch. I